肿瘤细胞治疗研究
英文原题：Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.
这些方法共同旨在为改善 AML 的免疫治疗结局提供新的见解。
急性髓系白血病（AML）的免疫治疗疗效仍显著受限于早期复发和治疗相关毒性。本综述考察AML抗体及细胞免疫治疗的近期进展，重点关注已确立靶点（CD33、CD123和CLL1）以及新兴靶点（包括CD7、CD70、CD38和FLT3）。讨论的治疗方式包括免疫偶联物、双特异性T细胞衔接器和CAR-T（CAR-T）细胞。此外，我们总结阻碍AML免疫治疗成功的当前挑战，并提出提高疗效的策略，包括联合治疗、优化CAR构建体结构、增强CAR-T细胞功能、发现新靶点及开发新一代细胞疗法。这些方法旨在为改善AML免疫治疗结局提供新思路。
The clinical efficacy of immunotherapy in acute myeloid leukemia (AML) remains significantly limited by early relapse and treatment-associated toxicities. This review examines recent advances in antibody- and cell-based immunotherapies for AML, focusing on established targets (CD33, CD123, and CLL1) as well as emerging targets (including CD7, CD70, CD38, and FLT3). Therapeutic modalities discussed include immunoconjugates, bispecific T-cell engagers and chimeric antigen receptor T (CAR-T) cells. Furthermore, we summarize the current challenges impeding the success of immunotherapy in AML and propose strategies to enhance its efficacy. These include combination therapies, structural optimization of CAR constructs, functional enhancement of CAR-T cells, identification of novel targets, and the development of next-generation cellular therapies. Collectively, these approaches aim to offer new insights for improving immunotherapeutic outcomes in AML.
MEMBER ACCOUNT
登录成功会直接打开下一页。
